Coley, Pfizer start NSCLC Phase IIIs

COLY and PFE started two Phase III trials of PF-3512676/ CPG 7909 (formerly ProMune) to treat non-small cell lung cancer (NSCLC). The primary endpoint of both international trials is overall survival....